封面
市場調查報告書
商品編碼
1499414

膠原蛋白疾病血管疾病市場:按產品、適應症和最終用途 - 全球預測 2024-2030

Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2024-2030

出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

膠原病血管疾病市場規模預計2023年為298.3億美元,2024年達322.1億美元,預計2030年將達535.1億美元,複合年成長率為8.70%。

膠原血管疾病是一組涉及支持器官和身體其他部位的富含蛋白質的組織的疾病。這種結締組織對於皮膚、肌腱、骨骼、軟骨和血管的強度、彈性和結構至關重要。膠原病血管疾病可能是遺傳性的,也可能是由過度活躍的免疫系統引起的,導致身體攻擊自身組織的自體免疫疾病。這些疾病通常具有通用特徵,包括導致受影響器官和組織受損和功能障礙的發炎。此類別包括多種疾病,包括類風濕性關節炎、硬皮症、全身性紅斑性狼瘡、多發性肌炎、皮肌炎和全身性硬化症。膠原病血管疾病市場涵蓋醫療解決方案的需求和供應,例如針對影響結締組織的疾病的診斷、治療、療法和服務。該市場的應用包括臨床診斷、治療和持續的患者管理。最終使用者通常是醫療機構,例如醫院、診所、風濕病中心和居家照護機構。該市場也為研究和學術機構以及參與開發新治療方法的製藥和生物技術公司提供服務。影響膠原血管疾病市場需求的關鍵因素是:人們對膠原血管疾病的認知和理解不斷提高、全球自體免疫疾病盛行率上升、醫療保健基礎設施的改善以及醫療服務的可及性的改善。然而,他們面臨挑戰,例如與先進治療和藥物相關的高成本,以及嚴格的政府法規和核准流程。同時,膠原血管疾病的需求帶來了一些快速成長的機會,包括基因治療和幹細胞治療的進步,以及遠端醫療、行動醫療應用和穿戴式裝置在患者管理中的採用。

主要市場統計
基準年[2023] 298.3億美元
預測年份 [2024] 322.1億美元
預測年份 [2030] 535.1億美元
複合年成長率(%) 8.70%

區域洞察

美國因其完善的醫療基礎設施、患者意識以及自體免疫疾病的高盛行率而成為心血管疾病的重要市場。專注於技術創新的大型製藥企業的存在和政府的支持政策正在促進市場的擴張。在南美洲,隨著醫療保健的改善和人們對這種疾病的認知不斷提高,膠原蛋白血管疾病市場正在擴大。政府加強醫療保健服務和醫學研究國際合作的措施預計將進一步提振市場。歐盟對 KEYWORD 的需求的特徵是全民健保系統的可用性以及對研究和開發的重視。嚴格的藥品核准規定確保了高標準的醫療服務。該地區的消費者期待最先進的治療設施,並受到治療的功效和安全性的驅動。包括膠原血管疾病在內的自體免疫疾病在中東呈上升趨勢,發展中的醫療保健產業高度依賴國際指南和藥物。非洲治療膠原血管疾病的能力各不相同,許多地區這些疾病的盛行率很高,而且缺乏先進的治療方法。隨著向現代醫療保健體系的過渡,中國市場正在迅速擴張,政府和私營部門對醫療保健的投資不斷增加,全球藥品的取得也不斷改善,影響著客戶的需求。日本市場反映了醫療保健領域技術整合的高水平,消費者基礎傾向於創新和護理品質。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在膠原病血管疾病市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。

市場佔有率分析

市場佔有率分析是一種綜合工具,可以對膠原血管疾病市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對他們目前在膠原病血管疾病市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對膠原血管疾病的認知與了解
      • 全球自體免疫疾病的發生率上升
      • 改善醫療基礎設施並增加獲得醫療服務的機會
    • 抑制因素
      • 與先進治療和藥物相關的高成本
    • 機會
      • 基因和幹細胞治療的持續進展
      • 部署遠端醫療、行動醫療應用程式和穿戴式裝置進行病患管理
    • 任務
      • 嚴格的政府法規和核准流程
  • 市場區隔分析
    • 產品:切片檢查套件在膠原血管疾病的使用增加
    • 適應症:越來越多用於皮肌炎
    • 最終用途:擴大在診斷中心和實驗室的用途,以診斷各種健康狀況
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章膠原蛋白疾病血管疾病市場:依產品

  • 診斷
  • 治療

第7章膠原蛋白疾病血管疾病市場(按適應症)

  • 僵直性脊椎炎
  • 皮肌炎
  • 結節性多動脈炎
  • 多發性肌炎
  • 乾癬性關節炎
  • 復發性多發性軟骨炎
  • 類風濕性關節炎
  • 硬皮症
  • 全身性紅斑性狼瘡
  • 血管炎

第8章膠原病血管疾病市場:依最終用途分類

  • 診斷中心及實驗室
  • 醫院/診所

第9章 北美和南美膠原蛋白疾病血管疾病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區膠原蛋白疾病血管疾病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲膠原病血管疾病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
    • Quest Diagnostics 與 Cipher Medicine 合作,擴大類風濕性關節炎患者獲得精準醫療的機會
    • FDA核准首個托珠單抗生物相似藥用於治療類風濕性關節炎、幼年類風濕性關節炎
    • 美國風濕病學會推出新套件來衡量類風濕性關節炎的結果
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-144C638C8F82

[184 Pages Report] The Collagen Vascular Diseases Market size was estimated at USD 29.83 billion in 2023 and expected to reach USD 32.21 billion in 2024, at a CAGR 8.70% to reach USD 53.51 billion by 2030.

Collagen vascular diseases comprise a group of disorders that involve the protein-rich tissue that supports organs and other parts of the body. This connective tissue is essential for the strength, elasticity, and structure of skin, tendons, bones, cartilage, and blood vessels. Collagen vascular diseases can be hereditary or caused by an overactive immune system, resulting in autoimmune conditions where the body attacks its own tissues. These diseases often share common features, including inflammation, which can damage and dysfunction of affected organs and tissues. The category encompasses a variety of conditions, including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, and systemic sclerosis, among others. The market for collagen vascular diseases encompasses the demand and supply of medical solutions, including diagnostics, treatments, therapeutics, and services targeted towards diseases that affect connective tissue. Applications for this market include clinical diagnostics, therapeutic treatments, and ongoing patient management. End-users are typically healthcare facilities like hospitals, clinics, specialized rheumatology centers, and home care settings. This market also serves research and academic institutions and pharmaceutical and biotechnology companies involved in the development of new treatments. The key factors influencing the need for the collagen vascular diseases market include growing awareness and understanding of collagen vascular diseases, rising incidence of autoimmune diseases globally, improved healthcare infrastructure, and increased accessibility to medical services. However, the market faces challenges, such as high costs associated with advanced treatments and medications and stringent government regulations and approval processes. On the other hand, the need for collagen vascular diseases presents several burgeoning opportunities, such as ongoing advancements in gene and stem cell therapies and the adoption of telemedicine, mobile health applications, and wearables for patient management.

KEY MARKET STATISTICS
Base Year [2023] USD 29.83 billion
Estimated Year [2024] USD 32.21 billion
Forecast Year [2030] USD 53.51 billion
CAGR (%) 8.70%

Regional Insights

The United States represents a significant market for collagen vascular diseases (CVDs), driven by a well-established healthcare infrastructure, patient awareness, and a high incidence of autoimmune diseases. The presence of leading pharmaceutical companies focusing on innovation, coupled with supportive government policies, contributes to market expansion. In South America, the collagen vascular diseases market is expanding as healthcare access improves and the population becomes more aware of these diseases. Government initiatives to strengthen healthcare provision and international collaborations for medical research are expected to propel the market further. The EU's need for collagen vascular diseases is characterized by the availability of universal healthcare systems and a strong focus on research and development. Stringent regulations regarding drug approvals ensure a high standard of care. Consumers in this region expect state-of-the-art treatment facilities and are driven by the effectiveness and safety profiles of treatments. The Middle East is experiencing a rise in autoimmune disorders, including collagen vascular diseases, and due to a developing healthcare sector, there is a reliance on international guidelines and medications. Africa's capacity to manage collagen vascular diseases is varied, with a greater prevalence of these conditions and a scarcity of advanced treatments in many regions. China's market is rapidly expanding with a shift towards modern healthcare systems, and increased investment in healthcare by the government and private sector, paired with greater access to global pharmaceuticals, is influencing customer needs. Japan's market reflects a high degree of technological integration in healthcare, with a consumer base inclined towards innovation and treatment quality.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Collagen Vascular Diseases Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing awareness and understanding of collagen vascular diseases
      • Rising incidence of autoimmune diseases globally
      • Improved healthcare infrastructure and increased accessibility to medical services
    • Market Restraints
      • High cost associated with advanced treatments and medications
    • Market Opportunities
      • Ongoing advancements in gene and stem cell therapies
      • Adoption of telemedicine, mobile health applications, and wearables for patient management
    • Market Challenges
      • Stringent government regulations and approval processes
  • Market Segmentation Analysis
    • Product: Increasing usage of biopsy kits in collagen vascular diseases
    • Indication: Increasing utilization for indicating dermatomyositis
    • End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Collagen Vascular Diseases Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Collagen Vascular Diseases Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis

Quest Diagnostics and Scipher Medicine have forged a multi-year partnership to widen the scope of diagnostic capabilities for rheumatoid arthritis (RA) management, leveraging the pioneering PrismRA test. This molecular signature response classifier (MSRC) facilitates the prediction of responses to TNF inhibitor therapies, which is crucial for managing RA. Quest's service extension to include advanced RNA extraction and next-generation sequencing ensures a more efficient assessment of patient responses to TNF inhibitors. The partnership capitalizes on Quest's nationwide network for specimen collection and sophisticated logistics, thereby enhancing patient access to precision diagnostic solutions. [Published On: 2023-11-28]

FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA

Biogen has announced the FDA approval of Tofidence, the inaugural tocilizumab biosimilar authorized for use in the U.S., offering new treatment options for individuals with rheumatoid arthritis (RA) and certain juvenile arthritis conditions. This milestone promises increased healthcare savings and broader therapeutic access, according to the details provided by the manufacturer. Tofidence has been validated based on rigorous data analysis, including a phase 1 and phase 3 study, affirming its safety and efficacy as a biosimilar alternative to the reference drug Actemra. [Published On: 2023-10-02]

American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes

The American College of Rheumatology (ACR) has introduced its innovative Rheumatoid Arthritis (RA) Measures Toolkit, a comprehensive resource designed to dramatically enhance the quality of RA patient care. Emphasizing the importance of regular monitoring and individualized therapy, the toolkit offers invaluable tools, including training guides, multilingual outcome measure copies, and workflow samples, to ensure precise and effective tracking of disease activity and patient functionality. [Published On: 2023-08-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Collagen Vascular Diseases Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Collagen Vascular Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Diagnosis
      • Biopsy
      • Blood Test
      • Echocardiogram
      • Imaging Tests
      • Urinalysis
    • Treatments
      • Medications
      • Physical Therapy
  • Indication
    • Ankylosing Spondylitis
    • Dermatomyositis
    • Polyarteritis Nodosa
    • Polymyositis
    • Psoriatic Arthritis
    • Relapsing Polychondritis
    • Rheumatoid Arthritis
    • Scleroderma
    • Systemic Lupus Erythematosus
    • Vasculitis
  • End-Use
    • Diagnostic Centers & Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and understanding of collagen vascular diseases
      • 5.1.1.2. Rising incidence of autoimmune diseases globally
      • 5.1.1.3. Improved healthcare infrastructure and increased accessibility to medical services
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in gene and stem cell therapies
      • 5.1.3.2. Adoption of telemedicine, mobile health applications, and wearables for patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing usage of biopsy kits in collagen vascular diseases
    • 5.2.2. Indication: Increasing utilization for indicating dermatomyositis
    • 5.2.3. End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Collagen Vascular Diseases Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnosis
  • 6.3. Treatments

7. Collagen Vascular Diseases Market, by Indication

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Dermatomyositis
  • 7.4. Polyarteritis Nodosa
  • 7.5. Polymyositis
  • 7.6. Psoriatic Arthritis
  • 7.7. Relapsing Polychondritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Scleroderma
  • 7.10. Systemic Lupus Erythematosus
  • 7.11. Vasculitis

8. Collagen Vascular Diseases Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Laboratories
  • 8.3. Hospitals & Clinics

9. Americas Collagen Vascular Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Collagen Vascular Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Collagen Vascular Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
    • 12.3.2. FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA
    • 12.3.3. American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. COLLAGEN VASCULAR DISEASES MARKET DYNAMICS
  • FIGURE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 315. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 316. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 326. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2